STOCK TITAN

Wellgistics Health (WGRX) CEO converts 100,000 warrants into shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Wellgistics Health, Inc. Chief Executive Officer Prashant Patel exercised compensation-related warrants into common stock. On June 22, 2026, he exercised warrants covering 100,000 shares of common stock at an exercise price of $0.005 per share, converting them into common shares.

The warrants were originally issued to him on March 31, 2026 in lieu of cash compensation. Following a reverse stock split effective May 26, 2026 and this warrant conversion, Patel now directly holds a total of 282,365 shares of Wellgistics common stock.

Positive

  • None.

Negative

  • None.
Insider Patel Prashant
Role Chief Executive Officer
Type Security Shares Price Value
X Warrant 100,000 $0.00 --
X Common Stock 100,000 $0.005 $500.00
Holdings After Transaction: Warrant — 0 shares (Direct); Common Stock — 282,365 shares (Direct)
Footnotes (1)
  1. Represents the conversion of warrants (the "Warrants") issued to the Reporting Person on 3/31/2026 in lieu of cash compensation due to the Reporting Person. Reflects the aggregate amount of Common Stock held by the Reporting Person following the Issuer's reverse stock split, effective May 26, 2026, as well as the Common Stock issued pursuant to the conversion of the Warrants.
Common shares from exercise 100,000 shares Common Stock acquired via warrant exercise on June 22, 2026
Exercise price $0.005 per share Exercise price of warrants converted into common stock
Post-transaction holdings 282,365 shares Total Common Stock held directly by CEO after reverse split and conversion
Warrants exercised 100,000 warrants Derivative position in Warrants converted into Common Stock
Warrant expiration March 31, 2031 Original expiration date of the Warrants before full exercise
in-the-money derivative exercise financial
"transaction_action: in-the-money derivative exercise for Common Stock and Warrants"
Warrants financial
"Represents the conversion of warrants (the "Warrants") issued to the Reporting Person"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
in lieu of cash compensation financial
"Warrants issued to the Reporting Person on 3/31/2026 in lieu of cash compensation"
reverse stock split financial
"following the Issuer's reverse stock split, effective May 26, 2026"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Wellgistics Health (WGRX) report for its CEO?

Wellgistics Health reported that CEO Prashant Patel exercised warrants for 100,000 shares of common stock at $0.005 per share. The warrants were compensation issued in lieu of cash, and the exercise converted them into additional common shares he now holds directly.

How many Wellgistics Health (WGRX) shares does the CEO hold after this Form 4?

After the warrant exercise and reflecting a reverse stock split effective May 26, 2026, CEO Prashant Patel directly holds 282,365 shares of Wellgistics common stock. This total includes both previously held shares and the 100,000 shares issued upon conversion of the warrants.

What were the terms of the warrants exercised by the Wellgistics (WGRX) CEO?

The warrants exercised by CEO Prashant Patel covered 100,000 underlying common shares with an exercise price of $0.005 per share. They were issued to him on March 31, 2026 as compensation in lieu of cash and were later fully converted into common stock.

Did the Wellgistics Health (WGRX) CEO sell any shares in this Form 4 filing?

The Form 4 shows no sales by CEO Prashant Patel. It reports only the in-the-money exercise of warrants into 100,000 shares of common stock, increasing his direct share ownership, with the warrant position reduced to zero after the conversion.

How is the Wellgistics (WGRX) reverse stock split reflected in the CEO’s holdings?

The CEO’s post-transaction holdings of 282,365 common shares reflect the company’s reverse stock split effective May 26, 2026. This figure also incorporates the additional common stock issued when his 100,000-share warrant position was converted into common shares.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Patel Prashant

(Last)(First)(Middle)
C/O WELLGISTICS HEALTH, INC.
3000 BAYPORT DRIVE, SUITE 950

(Street)
TAMPA, FLORIDA 33607

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Wellgistics Health, Inc. [ WGRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/22/2026X100,000(1)A$0.005282,365D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrant$0.00506/22/2026X100,000(2)03/31/202603/31/2031Common Stock100,000$00D
Explanation of Responses:
1. Represents the conversion of warrants (the "Warrants") issued to the Reporting Person on 3/31/2026 in lieu of cash compensation due to the Reporting Person.
2. Reflects the aggregate amount of Common Stock held by the Reporting Person following the Issuer's reverse stock split, effective May 26, 2026, as well as the Common Stock issued pursuant to the conversion of the Warrants.
/s/ Prashant Patel06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)